

04 Dec 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer's meeting; China COVID unrest affect country's biotech sector; and Merck's CMO talks about post-Keytruda plans.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 2 December 2022, including: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer's meeting; China COVID unrest affect country's biotech sector; and [Merck & Co., Inc.](#)'s CMO talks about post-Keytruda plans. (Note - only four stories are covered this time as one selection – on Blenrep's US withdrawal - was inadvertently selected again this week after being covered in last week's episode. Our sincere apologies for this.)

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Eisai/Biogen's Lecanemab Effective Across Endpoints, But Will Safety Limit Use?](#)" - Scrip, 30 Nov, 2022.)

(Also see "[How Much Amyloid Clearance, How Fast Is Needed To Slow Alzheimer's?](#)" - Scrip, 30 Nov, 2022.)

(Also see "[COVID Unrest, Health Sector Deep Freeze Hits Chinese Biotechs Hard](#)" - Scrip, 29 Nov,

2022.)

(Also see "[\*CMO Eliav Barr On Merck & Co.'s Post-Keytruda Game Plan\*](#)" - Scrip, 25 Nov, 2022.)

[\*Click here to explore this interactive content online\*](#) ✎